{
    "info": {
        "nct_id": "NCT03363373",
        "official_title": "A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone And/or Bone Marrow",
        "inclusion_criteria": "* Diagnosis of neuroblastoma as defined per International Neuroblastoma Response Criteria\n* High-risk neuroblastoma patients with either primary refractory disease or incomplete response to salvage treatment (in both cases including stable disease, minor response and partial response) evaluable in bone and/or bone marrow.\n* Life expectancy ≥ 6 months\nHealthy volunteers allowed\nMust have minimum age of 1 Year",
        "exclusion_criteria": "* Any systemic anti-cancer therapy, including chemotherapy or immunotherapy, within 3 weeks before 1st dose of GM-CSF\n* Evaluable neuroblastoma outside bone and bone marrow\n* Existing major organ dysfunction > Grade 2, with the exception of hearing loss, hematological status, kidney and liver function\n* Active life-threatening infection",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 1 Year",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 1 Year",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "Year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of neuroblastoma as defined per International Neuroblastoma Response Criteria",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of neuroblastoma",
                    "criterion": "neuroblastoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "as defined per International Neuroblastoma Response Criteria",
                    "criterion": "diagnosis definition standard",
                    "requirements": [
                        {
                            "requirement_type": "definition standard",
                            "expected_value": "International Neuroblastoma Response Criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy ≥ 6 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy ≥ 6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* High-risk neuroblastoma patients with either primary refractory disease or incomplete response to salvage treatment (in both cases including stable disease, minor response and partial response) evaluable in bone and/or bone marrow.",
            "criterions": [
                {
                    "exact_snippets": "High-risk neuroblastoma patients",
                    "criterion": "neuroblastoma risk category",
                    "requirements": [
                        {
                            "requirement_type": "risk category",
                            "expected_value": "high-risk"
                        }
                    ]
                },
                {
                    "exact_snippets": "primary refractory disease or incomplete response to salvage treatment (in both cases including stable disease, minor response and partial response)",
                    "criterion": "disease response status",
                    "requirements": [
                        {
                            "requirement_type": "response status",
                            "expected_value": [
                                "primary refractory disease",
                                "incomplete response to salvage treatment",
                                "stable disease",
                                "minor response",
                                "partial response"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "evaluable in bone and/or bone marrow",
                    "criterion": "disease evaluability in bone and/or bone marrow",
                    "requirements": [
                        {
                            "requirement_type": "evaluable site",
                            "expected_value": [
                                "bone",
                                "bone marrow"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Existing major organ dysfunction > Grade 2, with the exception of hearing loss, hematological status, kidney and liver function",
            "criterions": [
                {
                    "exact_snippets": "Existing major organ dysfunction > Grade 2, with the exception of hearing loss, hematological status, kidney and liver function",
                    "criterion": "major organ dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "Grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any systemic anti-cancer therapy, including chemotherapy or immunotherapy, within 3 weeks before 1st dose of GM-CSF",
            "criterions": [
                {
                    "exact_snippets": "Any systemic anti-cancer therapy, including chemotherapy or immunotherapy, within 3 weeks before 1st dose of GM-CSF",
                    "criterion": "systemic anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "administration_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks before 1st dose of GM-CSF"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "chemotherapy ... within 3 weeks before 1st dose of GM-CSF",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "administration_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks before 1st dose of GM-CSF"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "immunotherapy ... within 3 weeks before 1st dose of GM-CSF",
                    "criterion": "immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "administration_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks before 1st dose of GM-CSF"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evaluable neuroblastoma outside bone and bone marrow",
            "criterions": [
                {
                    "exact_snippets": "Evaluable neuroblastoma",
                    "criterion": "neuroblastoma",
                    "requirements": [
                        {
                            "requirement_type": "evaluable",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "outside bone and bone marrow",
                    "criterion": "neuroblastoma location",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "outside bone",
                                "outside bone marrow"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active life-threatening infection",
            "criterions": [
                {
                    "exact_snippets": "Active life-threatening infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "life-threatening"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}